Efficiency of triple antihypertensive therapy in patients with uncontrolled hypertension and depressive disorders


Cite item

Full Text

Abstract

Aim. To evaluate the efficiency of triple antihypertensive therapy in patients with uncontrolled hypertension and depressive disorders (DD). Materials and methods. 153 patients with uncontrolled hypertension were examined, of whom 82 patients were diagnosed with mild and moderate DD. A combination of perindopril 10 mg/day, indapamide SR 1.5 mg/day, and amlodipine at an initial dose of 5 mg/day was given to patients with hypertension and DD. After 4 weeks of treatment, if target blood pressure (BP) levels could not be achieved, the dose of amlodipine was increased up to 10 mg/day. General clinical examination and 24-hour BP monitoring (BPM) were performed in all the patients at baseline and in the patients with DD also after 24 weeks of therapy. The traditional measures of the diurnal BP profile, as well as the parameters characterizing arterial stiffness and central aortic pressure (CAP) were estimated. Results. After 8 weeks of therapy, target BP levels were recorded in 63 (76.8%) patients. After 24 weeks of treatment, the hypertensive patients with DD showed significant positive changes in all the investigated 24-hour BPM parameters and normalization of the diurnal BP profile in 65.1% of cases. During the treatment, there were significant decreases in pulse wave velocity, brachial arterial and aortic augmentation indices, aortic systolic and diastolic pressures, and mean aortic BP and an increase in the velocity of the reflected wave. Conclusion. Triple therapy, including perindopril, indapamide SR, and amlodipine, contributed to the achievement of target BP levels in the majority of hypertensive patients with DD, with significant positive changes in all 24-hour BPM parameters, optimization of the diurnal BP profile in most patients, clinically significant improvement of the parameters that characterize arterial stiffness and CAP.

About the authors

V V Skibitsky

ГБОУ ВПО «Кубанский государственный медицинский университет» Минздрава России

Краснодар, Россия

A V Fendrikova

ГБОУ ВПО «Кубанский государственный медицинский университет» Минздрава России

Краснодар, Россия

A V Skibitsky

ГБОУ ВПО «Кубанский государственный медицинский университет» Минздрава России

Краснодар, Россия

References

  1. Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Конради А.О., Либис Р.А., Минаков А. В., Недогода С. В., Ощепкова Е. В., Романчук С. А., Ротарь О. П., Трубачева И. А., Чазова И. Е., Шляхто Е. В. Артериальная гипертония среди лиц 25—64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 13(4):4-14. https://doi.org/10.15829/1728-8800-2014-4-4-14
  2. SPRINT Research Group., Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939
  3. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990—2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260. https://doi.org/10.1016/S0140-6736(12)61766-8
  4. Moise N, Davidson KW, Chaplin W, Shea S, Kronish I. Depression and clinical inertia in patients with uncontrolled hypertension. JAMA Intern Med. 2014;115. https://doi.org/10.1001/jamainternmed.2014.115
  5. Aikens JE, Nease DE Jr, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Annals of Family Medicine. 2005;3:23-30. https://doi.org/10.1370/afm.238
  6. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  7. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. https://doi.org/10.1016/S0140-6736(05)67185-1
  8. Roush GC, Sica DA. Diuretics for Hypertension: A Review and Update. Am J Hypertens. 2016;29(10):1130-1137. https://doi.org/10.1093/ajh/hpw030
  9. Недогода С.В., Чумачек Е.В., Ледяева А.А., Цома В.В., Саласюк А.С., Смирнова В.О., Хрипаева В.Ю., Палашкин Р.В. Оптимизация контроля артериального давления, органопротекции и метаболических нарушений с помощью фиксированной комбинации периндоприл и индапамида у пациентов с артериальной гипертензией. Кардиология. 2017;57(2):5-11. https://doi.org/10.18565/cardio.2017.2.5-11
  10. Остроумова О.Д. Эффективность и безопасность фиксированной комбинации периндоприла аргинина и амлодипина при неэффективности терапии блокаторами рецепторов к ангиотензину II в условиях реальной клинической практики (по результатам программы ПРЕВОСХОДСТВО). Кардиология. 2017;57(1):30-36.
  11. van Sloten TT, Mitchell GF, Sigurdsson S, van Buchem MA, Jonsson PV, Garcia ME, Harris TB, Henry RM, Levey AS, Stehouwer CD, Gudnason V, Launer LJ. Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study. J Psychiatry Neurosci. 2016;41(3):162-168. https://doi.org/10.1503/jpn.140334
  12. Steptoe A, Willemsen G, Owen N, Flower L, Mohamed-Ali V. Acute mental stress elicits delayed increases in circulating inflammatory cytokine levels. Clin Sci (Lond). 2001;101(2):185-192. https://doi.org/10.1042/cs1010185
  13. Зверева Т.Н., Чернявская Е.Ю., Барбараш О.Л. Влияние периндоприла на процессы субклинического воспаления у больных артериальной гипертензией и сахарным диабетом 2-го типа. Кардиология. 2013;53(4):19-24.
  14. Suliburska J, Krejpcio Z, Staniek H, Król E, Bogdanski P, Kupsz J, Hertig I. The effects of antihypertensive drugs on chromium status, glucose metabolism, and antioxidant and inflammatory indices in spontaneously hypertensive rats. Biol Trace Elem Res. 2014;157(1):60-66. https://doi.org/10.1007/s12011-013-9864-8
  15. Скибицкий В.В., Скибицкий А.В., Фендрикова А.В. Влияние комбинированной антигипертензивной терапии на показатели жесткости сосудистой стенки у больных с неконтролируемой артериальной гипертонией и депрессивными расстройствами. Российскийкардиологическийжурнал. 2016;4(132):76-82. https://doi.org/10.15829/1560-4071-2016-4-76-82
  16. Строкова Е.В., Наумова Е.А., Шварц Ю.Г. Приверженность длительному лечению кардиологических пациентов с легкой и умеренной депрессией: неэффективность антидепрессивной терапии пирлиндолом в рандомизированном исследовании. РФК. 2012;8(1):45-50.
  17. Mourad JJ, Amodeo C, de Champvallins M, Brzozowska-Villatte R, Asmar R. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens. 2017. https://doi.org/10.1097/HJH.0000000000001359

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies